the Breast Cancer Paradigm
Our mission is to develop innovative medicines in areas of significant unmet medical needs in oncology.
The Breast Cancer Problem
of US breast cancer is ER+
1 in 8
women experience breast cancer
women diagnosed in US annually
leading cause of cancer death in American women
Our Lead Program
Atossa’s primary focus is the development of our proprietary (Z)-endoxifen in multiple breast cancer settings.
We are developing the promise of (Z)-endoxifen in two different settings and exploiting its potential to both help prevent as well as treat breast cancer with our proprietary Oral (Z)-endoxifen.
The two settings of (Z)-endoxifen include Neoadjuvant ER+/HER2- and Mammographic Breast Density(MBD).